Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
Journal of Zhejiang University. Science. B ; (12): 630-637, 2008.
Article in English | WPRIM | ID: wpr-359371

ABSTRACT

<p><b>BACKGROUND</b>Bone marrow mesenchymal stem cell (MSC) transplantation is a promising strategy in the treatment of myocardial infarction (MI). However, the time for transplanting cells remains controversial. The aim of this study was to find an optimal time point for cell transplantation.</p><p><b>METHODS</b>MSCs were isolated and cultured from Sprague-Dawley (SD) rats. MI model was set up in SD rats by permanent ligation of left anterior descending coronary artery. MSCs were directly injected into the infarct border zone at 1 h, 1 week and 2 weeks after MI, respectively. Sham-operated and MI control groups received equal volume of phosphate buffered saline (PBS). At 4 weeks after MI, cardiac function was assessed by echocardiography; vessel density was analyzed on hematoxylin-eosin stained slides by light microscopy; the apoptosis of cardiomyocytes was evaluated by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay; the expressions of proteins were analyzed by Western blot.</p><p><b>RESULTS</b>MSC transplantation improved cardiac function, reduced the apoptosis of cardiomyocytes and increased vessel density. These benefits were more obvious in 1-week group than in 1-h and 2-week groups. There are more obvious increases in the ratio of bcl-2/bax and the expression of vascular endothelial growth factor (VEGF) and more obvious decreases in the expression of cleaved-caspase-3 in 1-week group than those in other two groups.</p><p><b>CONCLUSION</b>MSC transplantation was beneficial for the recovery of cardiac function. MSC transplantation at 1 week post-MI exerted the best effects on increases of cardiac function, anti-apoptosis and angiogenesis.</p>


Subject(s)
Animals , Male , Rats , Apoptosis , Cells, Cultured , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells , Cell Biology , Myocardial Infarction , Pathology , General Surgery , Rats, Sprague-Dawley , Time Factors
2.
Chinese Medical Journal ; (24): 155-160, 2008.
Article in English | WPRIM | ID: wpr-255748

ABSTRACT

<p><b>BACKGROUND</b>Mesenchymal stem cells are a promising cell type for cell transplantation in myocardial infarction. Type I neuregulins-1, also known as heregulin, can promote the survival of cardiomyocytes and stimulate angiogenesis. The purpose of this study was to investigate the expression of heregulin and ErbB receptors in mesenchymal stem cells, then further detect the secretion of heregulin and the changes in expression of heregulin and ErbB receptors under conditions of serum deprivation and hypoxia.</p><p><b>METHODS</b>Mesenchymal stem cells isolated from bone marrow of 180 g male Sprague-Dawley rats were cultured. Passage 3 cells were detected experimentally by regular reverse transcriptase-polymerase chain reaction (RT-PCR), quantitative real time PCR and Western blotting.</p><p><b>RESULTS</b>Heregulin and ErbB receptors were expressed in mesenchymal stem cells, and all three ErbB receptors mRNA expressions were significantly down-regulated by serum deprivation and hypoxia, but serum deprivation and hypoxia significantly increased the protein expression of heregulin. Serum deprivation and hypoxia more than 12 hours could induce the secretion of heregulin.</p><p><b>CONCLUSIONS</b>Mesenchymal stem cells can express all three ErbB receptors and heregulin. Serum deprivation and hypoxia decrease the mRNA expression of ErbB receptors, increase the expression of heregulin, and activate the secretion of heregulin.</p>


Subject(s)
Animals , Male , Rats , Cell Hypoxia , Cells, Cultured , Mesenchymal Stem Cells , Chemistry , Metabolism , Neuregulin-1 , Genetics , Oncogene Proteins v-erbB , Genetics , RNA, Messenger , Rats, Sprague-Dawley
3.
Journal of Zhejiang University. Science. B ; (12): 641-647, 2006.
Article in English | WPRIM | ID: wpr-251876

ABSTRACT

<p><b>OBJECTIVE</b>This study was performed to evaluate whether implantation of mesenchymal stem cell (MSC) would reduce left ventricular remodelling from the molecular mechanisms compared with angiotensin-converting enzyme inhibitors (ACEIs) perindopril into ischemic myocardium after acute myocardial infarction.</p><p><b>METHODS</b>Forty rats were divided into four groups: control, MSC, ACEI, MSC+ACEI groups. Bone marrow stem cell derived rat was injected immediately into a zone made ischemic by coronary artery ligation in MSC group and MSC+ACEI group. Phosphate-buffered saline (PBS) was injected into control group. Perindopril was administered p.o. to ACEI group and MSC+ACEI group. Six weeks after implantation, the rats were killed and heart sample was collected. Fibrillar collagen was observed by meliorative Masson's trichome stain. Western Blotting was employed to evaluate the protein expression of matrix metalloproteinase (MMP)-2, matrix metalloproteinase (MMP)-9 in infarction zone. The transcriptional level of MMP2, MMP9 and tissue inhibitor of matrix metalloproteinase (TIMP)-1 in infarction area was detected by reverse transcriptase PCR (RT-PCR) analysis.</p><p><b>RESULTS</b>The fibrillar collagen area, the protein expression of MMP2, MMP9 and the transcriptional level of MMP2, MMP9 mRNA in infarction zone reduced in MSC group, ACEI group, and MSC+ACEI group. No significant difference was detected in the expression of TIMP1 mRNA among the 4 groups.</p><p><b>CONCLUSION</b>Both MSC and ACEI could reduce infarction remodelling by altering collagen metabolism.</p>


Subject(s)
Animals , Male , Rats , Angiotensin-Converting Enzyme Inhibitors , Therapeutic Uses , Bone Marrow Cells , Cell Biology , Matrix Metalloproteinase 2 , Matrix Metalloproteinase 9 , Mesenchymal Stem Cell Transplantation , Myocardial Infarction , Pathology , Therapeutics , Myocardium , Perindopril , Therapeutic Uses , Rats, Sprague-Dawley , Tissue Inhibitor of Metalloproteinase-1 , Ventricular Remodeling
SELECTION OF CITATIONS
SEARCH DETAIL